Peter Mountford
Plus aucun poste en cours
Profil
Peter Mountford worked as the Chief Technology Officer & Executive Director at Asset Realisation Co. Ltd.
from 2010 to 2013.
He also worked as the Chief Technology Officer at Stem Cell Sciences Plc.
Anciens postes connus de Peter Mountford
| Sociétés | Poste | Fin |
|---|---|---|
Asset Realisation Co. Ltd.
 Asset Realisation Co. Ltd. Financial ConglomeratesFinance Asset Realisation Co. Plc is in Members Voluntary Liquidation and the company's affairs are subsequently being administered by Samantha Keen and Ian Carr of Grant Thornton UK LLP as joint liquidators. The company was previously called Stem Cell Sciences Plc but changed its name after selling its operating assets to Stem Cells, Inc. The company is developing and applying stem cells and stem cell technologies in biopharmaceutical research and cell-based therapies. The company owns a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. These include technologies to permit the generation of purified stem cells and their differentiated progeny for use in genetic, pharmacological and toxilogical screens. Moreover, these technologies can be utilized to provide pure populations of appropriate cell types for transplantation therapies. The operations are carried out through its four business units namely SC Proven, SC Licensing, SC Services and SC Therapy. The company operates in the United Kingdom and Australia. | Directeur Technique/Scientifique/R&D | 13/05/2013 |
| Stem Cell Sciences Plc | Directeur Technique/Scientifique/R&D | 07/04/2009 |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| Stem Cell Sciences Plc | Commercial Services |
Asset Realisation Co. Ltd.
Asset Realisation Co. Ltd. Financial ConglomeratesFinance Asset Realisation Co. Plc is in Members Voluntary Liquidation and the company's affairs are subsequently being administered by Samantha Keen and Ian Carr of Grant Thornton UK LLP as joint liquidators. The company was previously called Stem Cell Sciences Plc but changed its name after selling its operating assets to Stem Cells, Inc. The company is developing and applying stem cells and stem cell technologies in biopharmaceutical research and cell-based therapies. The company owns a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. These include technologies to permit the generation of purified stem cells and their differentiated progeny for use in genetic, pharmacological and toxilogical screens. Moreover, these technologies can be utilized to provide pure populations of appropriate cell types for transplantation therapies. The operations are carried out through its four business units namely SC Proven, SC Licensing, SC Services and SC Therapy. The company operates in the United Kingdom and Australia. | Finance |
